MYDA Advisors’s Protara Therapeutics TARA Stock Holding History

MYDA Advisors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,027	Closed	-$236K	–	233
2020 Q3	$236K	Buy	+14,027	New	+$325K	0.12%	99

Other funds holding TARA

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MYDA Advisors's TARA Position: Q4 2020 in Review

MYDA Advisors sold out of Protara Therapeutics (TARA) in Q4 2020, closing a stake of 14,027 shares — an estimated $236K sold.

MYDA Advisors first reported a position in TARA in Q3 2020 and held it in 1 quarter. The position peaked at $236K in Q3 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q4 2020.

MYDA Advisors reported no remaining Protara Therapeutics position as of Q4 2020 after selling out during the quarter.
MYDA Advisors sold 14,027 Protara Therapeutics shares in Q4 2020, an estimated $236K.
MYDA Advisors first reported a position in Protara Therapeutics in Q3 2020 and held it in 1 quarter.
MYDA Advisors's Protara Therapeutics position peaked at $236K in Q3 2020.
49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2020.

Based on MYDA Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.